Search

Your search keyword '"Maria L. Naylor"' showing total 31 results

Search Constraints

Start Over You searched for: Author "Maria L. Naylor" Remove constraint Author: "Maria L. Naylor"
31 results on '"Maria L. Naylor"'

Search Results

1. Bioequivalence of intramuscular and subcutaneous peginterferon beta-1a: results of a phase I, open-label crossover study in healthy volunteers

2. Matching comparisons of therapeutic efficacy suggest better clinical outcomes for patients treated with peginterferon beta-1a than with glatiramer acetate

3. Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multiple sclerosis

4. Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN

5. Global Peginterferon Beta-1a Tolerability Management Best Practices: A Nurse-Focused Delphi Approach

6. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies

7. Pharmacokinetics/pharmacodynamics by Race: Analysis of a Peginterferon β-1a Phase I Study

8. Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: A post hoc analysis of the randomized CombiRx trial

9. Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions

10. 1111 Increasing access and quality of care for individuals from underrepresented communities living with lupus: insights from qualitative interviews with patients and physicians

11. Pharmacokinetics/pharmacodynamics by race: Analysis of a peginterferon β-1a phase 1 study

12. Matching comparisons of therapeutic efficacy suggest better clinical outcomes for patients treated with peginterferon beta-1a than with glatiramer acetate

13. Bioequivalence of intramuscular and subcutaneous peginterferon beta-1a: results of a phase I, open-label crossover study in healthy volunteers

14. Matching-adjusted comparisons demonstrate better clinical outcomes in patients with relapsing multiple sclerosis treated with peginterferon beta-1a than with teriflunomide

15. Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multiple sclerosis

16. Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN

18. Peginterferon beta-1a every 2 weeks demonstrated better clinical outcomes than glatiramer acetate once-daily in patients with RRMS: Propensity score matching of phase 3 data from ADVANCE and CONFIRM

19. Peginterferon beta-1a reduces the number of black holes evolved from acute MRI lesions in newly diagnosed patients with relapsing-remitting multiple sclerosis: A post hoc analysis ADVANCE

20. Profiling DNA damage-induced phosphorylation in budding yeast reveals diverse signaling networks

21. 069 Peginterferon beta-1a improves clinical and radiological disease outcomes in patients who are newly diagnosed with relapsing-remitting multiple sclerosis (RRMS): subgroup analysis of advance

22. 070 Baseline characteristics and safety profile of patients with relapsing-remitting multiple sclerosis (RRMS) in the first interim analysis of the peginterferon BETA-1A treatment in the phase 4 plegridy observational program (POP)

23. DNA-Dependent Protein Kinase Catalytic Subunit Is Not Required for Dysfunctional Telomere Fusion and Checkpoint Response in the Telomerase-Deficient Mouse

24. Diminished lifespan and acute stress-induced death in DNA-PKcs-deficient mice with limiting telomeres

25. RAD51-Dependent Break-Induced Replication Differs in Kinetics and Checkpoint Responses from RAD51-Mediated Gene Conversion

26. Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression

27. Genetic Requirements for RAD51- andRAD54-Independent Break-Induced Replication Repair of a Chromosomal Double-Strand Break

28. Mrc1 phosphorylation in response to DNA replication stress is required for Mec1 accumulation at the stalled fork

29. Essential role of limiting telomeres in the pathogenesis of Werner syndrome

30. RAD51-independent break-induced replication to repair a broken chromosome depends on a distant enhancer site

Catalog

Books, media, physical & digital resources